We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Tool Rapidly Analyzes Gene Activities in Medical Images to Highlight Hidden Cancers

By LabMedica International staff writers
Posted on 03 Jan 2024
Print article
Image: A new AI tool brings precision pathology for cancer and beyond into quicker, sharper focus (Photo courtesy of 123RF)
Image: A new AI tool brings precision pathology for cancer and beyond into quicker, sharper focus (Photo courtesy of 123RF)

A novel artificial intelligence (AI) tool, designed to interpret medical images with exceptional clarity, is set to revolutionize the way clinicians approach disease diagnosis and image analysis.

This advanced tool, named iStar (Inferring Super-Resolution Tissue Architecture), was developed by researchers at the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA). It can assist healthcare professionals in diagnosing and treating cancers that might otherwise remain undetected. iStar offers an in-depth view of individual cells and a broader look at the full range of human gene activity, potentially revealing cancer cells that were nearly invisible earlier. This tool could play a crucial role in confirming whether cancer surgeries have fully removed malignancies and provide automatic annotations for microscopic images, marking a significant leap toward molecular-level disease diagnosis. One of the standout capabilities of iStar is its automatic identification of crucial anti-tumor immune formations known as "tertiary lymphoid structures," which are indicators of a patient's survival prospects and their likely response to immunotherapy. This precision makes iStar a powerful tool for selecting the right patients for immunotherapy treatments.

The researchers put iStar to the test across various cancer types, including breast, prostate, kidney, and colorectal cancers, alongside healthy tissue samples. In these trials, iStar automatically detected tumor and cancer cells that were challenging to spot with the naked eye. With iStar as an additional support layer, clinicians might soon be able to diagnose more elusive cancers effectively. Moreover, iStar operates at a remarkably fast pace compared to similar AI tools. In a trial with a breast cancer dataset, iStar completed its analysis in a mere nine minutes, whereas the closest competing AI tool took over 32 hours to deliver a comparable analysis. This makes iStar an astounding 213 times faster, offering a significant advantage in time-sensitive clinical environments.

“The power of iStar stems from its advanced techniques, which mirror, in reverse, how a pathologist would study a tissue sample,” explained Mingyao Li, Ph.D., a professor of Biostatistics and Digital Pathology. “Just as a pathologist identifies broader regions and then zooms in on detailed cellular structures, iStar can capture the overarching tissue structures and also focus on the minutiae in a tissue image.”

Related Links:
Perelman School of Medicine

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.